Published by Jessica Weisman-Pitts
Posted on March 3, 2023
The incidence of knee osteoarthritis is rising in Russia as a result of rising obesity rates and a fast ageing population. This factor is fueling the growth of the single injection viscosupplementation segment in the Russian viscosupplementation market.
NEWARK, Del : The growth of the viscosupplementation market Sales of viscosupplementation equipment are anticipated to reach US$ 1.98 Billion globally in 2022. According to a thorough research of the market, by 2030 the worldwide viscosupplementation market is expected to grow at a CAGR of 4.8% and be worth US$ 2.89 billion. Increase in the population suffering from osteoarthritis is creating high demand for osteoarthritis treatment and pain management drugs, which is expected to result in the robust growth of the viscosupplementation market.
The expanding aging population is a major driving factor driving the viscosupplementation market. Age is an important risk factor for osteoarthritis, and epidemiological studies demonstrate a rise in the prevalence of osteoarthritis with growing age. According to CDC, the prevalence of osteoarthritis was found to be the highest in populations aged between 65 and 75 years.
Viscosupplementation emerges as a prior and cost-effective treatment option to delay total knee replacement surgery, which is another major factor propelling the growth of the viscosupplementation market. Cost-analysis studies have shown that viscosupplementation delays the need to perform knee replacement by 2.6 years.
Sample Request@ https://www.futuremarketinsights.com/reports/sample/rep-gb-9509
Reimbursement cutbacks are among the major factors that are expected to hamper the growth of the viscosupplementation market. American Association of Orthopedic Surgeons (AAOS) revised the long-standing clinical practice guideline for hyaluronic acid injection in May 2013, after which AAOS cannot recommend hyaluronic acid injection for patients with symptomatic knee osteoarthritis.
Due to the AAOS response, most of the reimbursement payers continue deny reimbursements for hyaluronic acid injections. Moreover, the failure of clinical studies and the unavailability of FDA-approved hyaluronic acid injections for joints other than the knees are expected to restrain the growth of the viscosupplementation market.
Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-9509
Market in China to Demonstrate Significant Growth
The global viscosupplementation market has been studied based on the product type and end user. Based on the product type, the viscosupplementation market has been segmented into three-injection viscosupplementation, single-injection viscosupplementation, and five-injection viscosupplementation. The three-injection viscosupplementation segment is expected to hold the maximum market share in the global viscosupplementation market.
Based on end user, the viscosupplementation market has been segmented into hospitals, orthopedic clinics, and ambulatory surgery centers. In terms of revenue, the hospital segment of the viscosupplementation market dominated the global viscosupplementation market in 2018.
North America is expected to dominate the global viscosupplementation market. Although developed countries dominate the market, emerging markets represent higher growth opportunities for the viscosupplementation market. For instance, China is expected to witness the highest growth rate in the viscosupplementation market over the forecast period. Factors, such as rising healthcare facilities and disposable income, are expected to significantly boost the demand for viscosupplementation in the near future.
Manufacturers to Strategize on New Product Launches
Manufacturers in the viscosupplementation market follow different strategies to grow their businesses as well as to penetrate the viscosupplementation market. Viscosupplementation market players are focusing on distribution and marketing agreements to enhance their market presence.
For example market players such as Anika therapeutic, Bioventus LLC, Seikagaku Corporation, and Zimmer Biomet are focusing on distribution agreements for global market expansion. For instance, DePuy Mitek, Inc. has been distributing Anika Therapeutic’s Orthovisc and Monovisc viscosupplementation products for a long period. In addition, in 2018, Seikagaku Corporation extended its distribution agreement with Bioventus LLC for the distribution of its five injections hyaluronic acid product Supartz FX in the U.S.
Buy this report @ https://www.futuremarketinsights.com/checkout/9509
Manufacturers are focusing on the launch of new products in the U.S. market. Moreover, they are making efforts to receive approval for their hyaluronic acid-based products for the treatment of other types of joints, apart from the knees, in the U.S. market. Anika Therapeutics, Inc. is focusing on receiving FDA approval for its Cingal, hyaluronic acid, and corticosteroid combination injection.
Some of the key players operating in viscosupplementation market are Anika Therapeutics Inc., Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Ferring B.V., Seikagaku Corporation, Seikagaku Corporation, Chugai Pharmaceutical Co., Ltd., and Mylan N.V.
Key Segments of Viscosupplementation Industry Survey
Viscosupplementation Market by Product:
Viscosupplementation Market by Application:
Viscosupplementation Market by End User:
Full Report @ https://www.futuremarketinsights.com/reports/viscosupplementation-market
Table of Content
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
Have a Look at Related Research Reports of Healthcare
Localized Temperature Therapy Products Market share : The market for localised temperature therapy products is anticipated to reach US$ 1,752.9 million in 2023, growing to US$ 3,055.6 million in 2033. Positive market growth during the forecast period is indicated by a CAGR of 5.7%.
Chronic Pulmonary Hypertension Treatment Market Demand : The global chronic pulmonary hypertension therapy market is anticipated to reach a market size of US$ 7 billion in 2023 and US$ 11.4 billion by achieving a CAGR of 5% from 2023 to 2033.
Chronic Hepatitis B Virus Testing Market Analysis : The market for testing for chronic hepatitis B virus has a value of US$ 919 million in 2023 and is anticipated to grow to US$ 1790 million between 2023 and 2033, registering a CAGR of 6.9%.
PD-1/PD-L1 Inhibitors Market Opportunity : By 2023, the market for PD-1/PD-L1 inhibitors is anticipated to be worth US$ 49.5 billion, and by 2033, it is anticipated to be worth US$ 123.3 billion.
Fungal Testing Kits Market Growth : The fungal testing kits market poised to increase exponentially, surpassing US$ 4504 million by 2033, from a predicted market size of US$ 1.72 billion in 2023.
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
Explore more articles in the Research Reports category
